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Abstract. Liver ischemia represents a common clinical 
problem. In the present study, using an in vitro model of hepatic 
ischemia-reperfusion injury, we evaluated the potential cyto-
protective effect of the purine metabolites, such as adenosine 
and inosine, and studied the mode of their pharmacological 
actions. The human hepatocellular carcinoma-derived cell 
line HepG2 was subjected to combined oxygen-glucose 
deprivation (COGD; 0-14-24 h), followed by re-oxygenation 
(0-4-24 h). Adenosine or inosine (300-1,000 µM) were 
applied in pretreatment. Cell viability and cytotoxicity were 
measured by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide and lactate dehydrogenase methods, 
respectively. The results showed that both adenosine and 
inosine exerted cytoprotective effects, and these effects were 
not related to receptor-mediated actions, since they were not 
prevented by selective adenosine receptor antagonists. On 
the other hand, the adenosine deaminase inhibitor erythro-9-
(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA, 10 µM) 
markedly and almost fully reversed the protective effect of 
adenosine during COGD, while it did not influence the cyto-
protective effect of inosine in the same assay conditions. These 
results suggest that the cytoprotective effects are related to 
intracellular actions, and, in the case of adenosine also involve 
intracellular conversion to inosine. The likely interpretation 
of these findings is that inosine serves as an alternative source 
of energy to produce ATP during hypoxic conditions. The 
protective effects are also partially dependent on adenosine 
kinase, as the inhibitor 4-amino-5-(3-bromophenyl)-7-
(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, 2HCl 
(ABT 702, 30 µM) significantly reversed the protective effect 
of both adenosine and inosine during hypoxia and re-oxygen-
ation. Collectively, the current results support the view that 
during hypoxia, adenosine and inosine exert cytoprotective 
effects via receptor-independent, intracellular modes of 
action, which, in part, depend on the restoration of cellular 
bioenergetics. The present study supports the view that testing 
of inosine for protection against various forms of warm and 
cold liver ischemia is relevant.
Introduction
Liver ischemia-reperfusion is a common problem in many 
clinical conditions such as liver transplantation, hepatic failure 
after shock, and liver surgery. Liver reperfusion injury not only 
causes liver dysfunction, but also frequently induces injury in 
extrahepatic organs, including the lung, the kidney and the 
heart (1,2). Understanding the pathophysiological process of 
liver reperfusion injury is clinically and pathophysiologically 
important.
Ischemic preconditioning, which is defined as multiple 
cycles of brief ischemia and reperfusion before a prolonged 
ischemic insult, has been reported to exert protection in several 
organs, resulting in increased tolerance toward organ hypoxia. 
Ischemic preconditioning has been shown to attenuate the 
tissue injury observed after reperfusion of the liver (3-5). 
Several mediators, including adenosine, have been shown 
to play a crucial role in the protective response of ischemic 
preconditioning (3-6).
In the present study, we focused on adenosine and its 
endogenous metabolic derivate, inosine, to observe their 
effects in an in vitro model of liver I-R injury. For a long time 
inosine was considered to be an inactive metabolite. However, 
several studies have shown that it has immunomodulatory, 
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neuroprotective, cardioprotective and cytoprotective effects 
(7-10). These effects have been attributed to several indepen-
dent mechanisms. First, inosine can bind to A2A adenosine 
receptors activating several receptor dependent intracellular 
signaling pathways (11,12). Second, previous studies showed 
in kidney epithelial cells that inosine serves as an alterna-
tive substrate for ATP generation during hypoxia (13,14). 
Third, inosine (but not adenosine) can inhibit the activation 
of poly(ADP-ribose) polymerase enzyme (PARP) preserving 
cells from a suicidal utilization of NAD+ and ATP and, subse-
quently, cell death (15).
In this study, we evaluated the potential cytoprotective 
effects of adenosine and inosine in a cell-based model of liver 
I-R injury and pharmacologically characterized their mode of 
action.
Materials and methods
Materials. Adenosine, inosine, 8-cyclopentyl-1,3-dipropylx-
anthine (CDPX), 8-(3-chlorostyryl) caffeine (CSC), alloxazine, 
MRS 1523 and erythro-9-(2-hydroxy-3-nonyl) adenine hydro-
chloride (EHNA) were obtained from Sigma-Aldrich (St. Louis, 
MO, USA). 4-amino-5-(3-bromophenyl)-7-(6-morpholino-
pyridin-3-yl)pyrido[2,3-d]pyrimidine, 2HCl (ABT 702) was 
purchased from Calbiochem-Merck, Darmstadt, Germany. The 
receptor antagonists and ABT 702 were dissolved in dimethyl-
sulfoxide (DMSO): dilutions were made in phosphate-buffered 
saline (PBS, pH 7.4) to obtain a final 0.5% DMSO content 
in the assay volume. EHNA was dissolved in distilled water. 
Adenosine and inosine were dissolved in DMEM.
Cell culture. The human hepatocellular carcinoma-derived 
cell line HepG2 was obtained from the European Collection 
of Cell Cultures (Salisbury, UK) and maintained in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 4.5 g/l 
glucose and 10% fetal bovine serum (Invitrogen, Carlsbad, CA, 
USA), 4 mM glutamine, 100 IU/ml penicillin and 100 µg/ml 
streptomycin. Five days prior to the assay 10,000 cells/well 
were plated into 96-well tissue culture plates and cultured at 
37˚C in a 5% CO2 atmosphere. Cells from passage numbers 
9-25 were used for subsequent assays.
In vitro liver ischemia-reperfusion model. We developed 
a cell-based assay of liver ischemia-reperfusion in HepG2 
human liver epithelial cells. HepG2 cells were plated into 
96-well tissue culture plates. Cells were cultured for 5 days 
to form a confluent monolayer for the following assay. 
Culture medium was replaced with DMEM containing no 
glucose (Biochrom AG, Berlin, Germany) prior to induction 
of hypoxia. Culture plates were placed in gas-tight incuba-
tion chambers (Billups-Rothenberg Inc., Del Mar, CA, USA) 
and the chamber atmosphere was replaced by flushing the 
chamber with 95% N2: 5% CO2 mixture at 25 l/min flow rate 
for 5 min. The hypoxic chamber was sealed and incubated at 
37˚C for various time periods. Following hypoxia, the culture 
medium was removed and fresh DMEM containing 4.5 g/l 
glucose supplemented with 10% serum was added and the 
cells underwent re-oxygenation at 37˚C in a 5% CO2 atmo-
sphere for various time periods depending on the specific 
experimental protocol. Cells exposed to hypoxia in complete 
culture medium served as controls (CTL), as no reduction 
was detected in cell viability compared to cells maintained in 
normal culture conditions (complete culture medium, 5% CO2 
atmosphere, 37˚C), if HepG2 cells were exposed to oxygen 
depletion with culture medium containing 4.5 g/l glucose and 
10% serum for 24 h.
Inosine and adenosine proved to be markedly cytoprotective 
in our in vitro cell-based assay of liver I-R injury. In various 
studies we tested different periods of hypoxia (0-14-24 h) and 
subsequent re-oxygenation (0-4-24 h) in HepG2 cultures. Four 
groups were studied (n=24 for each group). The first group 
received pretreatment with adenosine, while the second group 
was pretreated with inosine prior to combined oxygen-glucose 
deprivation (COGD) conditions (from 300-1,000 µM, applied 
10 min before hypoxia). The third group (control) was subjected 
to COGD with drug vehicle only. The fourth group was the 
negative control group of the assay in which the cells were 
cultured in glucose containing medium (4.5 g/l) during the entire 
assay period. At the end of the experiments 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
viability and lactate dehydrogenase (LDH) cytotoxicity assays 
were conducted as described below.
Pharmacological characterization of the cytoprotective effects 
of adenosine and inosine in the in vitro model of liver I-R. The 
concentration-dependence of the cytoprotective effects was 
tested in HepG2 cells subjected to COGD with adenosine or 
inosine pretreatment (1, 3, 10, 30, 100, 300, 1,000-3,000 µM, 
n=3 each). The effects of adenosine and inosine were compared 
on the same 96-well tissue culture plate. A1 adenosine receptor 
antagonist CDPX (16,17), selective A2A antagonist CSC (18,19), 
the selective A2B adenosine receptor antagonist alloxazine (20), 
and the A3 adenosine receptor antagonist MRS 1523 (21,22) 
were added 30 min prior to adenosine or inosine (300 µM) in 
the indicated concentration prior to COGD. The cytotoxicity of 
receptor antagonists was also tested under normoxic conditions.
The adenosine deaminase inhibitor EHNA (23) and the 
adenosine kinase inhibitor ABT 702 (24,25) were applied at 
10 and 30 µM prior to administering adenosine or inosine and 
COGD. The combined administration of EHNA and ABT 702 
was also investigated. In all analyses, all relevant assay 
conditions (including adenosine receptor antagonists assays, 
adenosine and inosine comparisons) were represented on the 
same 96-well tissue culture plate to prevent inter-plate assay 
variability. The experiments were repeated independently at 
least three times.
MTT cell viability assay. To estimate the number of viable cells, 
MTT was added to the cells at a final concentration of 0.5 mg/ml 
and cultured at 37˚C in a 5% CO2 atmosphere for 1 h (26). The 
incubation medium was removed and the converted formazan 
dye was dissolved in isopropanol and measured at 570 nm with 
background measurement at 690 nm on a PowerWave reader 
(BioTek Instruments,. Inc., Winooski, VT, USA). A calibration 
curve was created by measuring the converting capacity of 
MTT of serial dilutions of HepG2 cells. The viable cell count 
was calculated using Gen5 data reduction software.
LDH cytotoxicity assay. Cell culture supernatant (30 µl) was 
mixed with 100 µl freshly prepared LDH assay reagent to reach 
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final concentrations of 85 mM lactic acid, 1040 mM nicotin-
amide adenine dinucleotide, 224 mM N-methylphenazonium 
methyl sulfate, 528 mM 2-(4-iodophenyl)-3-(4-nitrophenyl)-
5-phenyl-2H-tetrazolium chloride and 200 mM Tris (pH 8.2). 
The changes in absorbance were read kinetically at 492 nm for 
15 min. LDH activity values are shown as Vmax in mOD/min 
for kinetic assay (27).
Statistical analysis. Data are shown as the means ± SEM. 
One-way ANOVA was used to detect differences between 
groups. Post hoc comparisons were made using Tukey's test. A 
value of P<0.05 was considered to indicate statistically signifi-
cant differences. All statistical calculations were performed 
using GraphPad Prism 5 analysis software.
Results
Characterization of an in vitro liver ischemia-reperfusion 
model in HepG2 cells. To develop a reproducible in vitro 
liver ischemia reperfusion model on HepG2 liver epithe-
lial cells, we tested different periods (12, 14 and 24 h) of 
COGD, followed by a subsequent re-oxygenation period of 
4 h (Fig. 1). Twelve hours of hypoxia combined with 4 h of 
re-oxygenation did not induce a significant decline of the cell 
viability (data not shown). However, 14 h of hypoxia combined 
with 4 h re-oxygenation induced a significant decline of the 
cell viability. Furthermore, 24 h of hypoxia followed by a 4 h 
re-oxygenation period markedly reduced cellular viability in 
all groups, as detected by MTT viability assay. Both 14 and 
24 h of COGD were associated with a significant elevation of 
LDH activity detected in the cell culture supernatant (Fig. 1).
Various re-oxygenation periods (0-4-24 h) were also 
investigated after 14 h-long COGD. Increased cell injury was 
detected through the progression of the re-oxygenation period, 
as measured by both MTT and LDH assays (Fig. 2). Overall, 
these data indicate that in the current assay a substantial degree 
of cell injury occurs during the hypoxic period.
Effects of adenosine and inosine in an in vitro model of liver 
ischemia-reperfusion. Adenosine and inosine significantly 
protected against the loss of cell viability of HepG2 cultures 
during 14 and 24 h of the COGD group, and reduced LDH 
release from the cells (Fig. 3). Although adenosine and inosine 
significantly protected HepG2 cultures from 14 h hypoxia 
injury, during the progression of the re-oxygenation phase 
a progressive reduction in cell viability and enhanced LDH 
enzyme release were detected in all groups, as assessed by 
the MTT and LDH assays. These findings are consistent with 
the hypothesis that an extended hypoxia results in further cell 
damage during the reoxygenation (reperfusion) phase. Thus 
Figure 1. Viability and LDH activity are shown in HepG2 cultures during 
different periods of combined oxygen-glucose deprivation (COGD) and fol-
lowing a 4 h-long re-oxygenation. (A) Percent viability values by MTT assay 
and (B) LDH activities in mOD/min are shown. Each group, except the con-
trol (CTL) group, was incubated in glucose-free medium under anaerobic 
conditions for 14- or 24-h periods and a subsequent 4 h-long re-oxygenation 
phase by normalizing glucose and oxygen levels in the cell culture medium 
and atmosphere. Data are shown as the means ± SEM (n=24 for each group). 
White bar is control (CTL) group, black bar is COGD group during COGD 
without any pharmacological pretreatment, dotted bar shows 300 µM ade-
nosine (ADE) pretreatment group and ruled bar represents 300 µM inosine 
(INO) pretreatment group. ADE and INO groups were also under COGD 
conditions. #P<0.05 compared to the CTL group and *P<0.05 compared to 
the COGD group.
Figure 2. Viability and LDH activity are shown in HepG2 cultures during 
a 14 h-long combined oxygen-glucose deprivation (COGD) and following 
0-4-24 h of re-oxygenation. (A) Percent viability values by MTT and 
(B) LDH activities in mOD/min are shown. Each group, except the control 
(CTL) group, was incubated in glucose-free medium under anaerobic condi-
tions for a 14 h-long period and following a 0-4-24 h-long re-oxygenation 
phase by normalizing glucose and oxygen levels in the cell culture medium 
and atmosphere. Data are shown as the means ± SEM (n=24 for each group). 
White bar is control (CTL) group, black bar is COGD group during COGD 
without any pharmacological pretreatment, dotted bar shows 300 µM 
adenosine (ADE) pretreatment group and ruled bar represents inosine pre-
treatment group at 300 µM (INO). ADE and INO groups were also under 
COGD conditions. #P<0.05 compared to the CTL group and *P<0.05 com-
pared to the COGD group.
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our in vitro model clearly demonstrates the main aspects of 
the in vivo liver ischemia-reperfusion injury, with subsequent 
secondary injury occurring in the reperfusion phase.
Pharmacological characterization of the effects of adenosine 
and inosine in an in vitro liver ischemia-reperfusion model. 
For subsequent in-depth characterization of the effects of 
adenosine and inosine, we selected 14 h of hypoxia and 4 h 
of re-oxygenation periods as the standard assay conditions. 
First, we established a dose-response comparison between 
the cytoprotective effects of adenosine and inosine, by testing 
each compound in a concentration range of 1 µM - 3 mM. 
Adenosine and inosine showed cytoprotective effects already 
at 300 µM, and reached their maximum cytoprotective effect 
at 1,000 µM (Fig. 3). Adenosine and inosine partially attenu-
ated cellular LDH release, starting already at the concentration 
of 3 µM (Fig. 3).
We next evaluated the potential involvement of adenosine 
receptors in the protective effects of adenosine and inosine. 
Cells were pretreated with the adenosine receptor antagonists 
CDPX, CSC, alloxazine, and MRS 1523 prior to administra-
tion of cytoprotective concentrations (300 µM) of adenosine or 
inosine. None of the adenosine receptor antagonists affected the 
cytoprotective effects of adenosine and inosine during COGD 
and following a 4 h-long re-oxygenation period (Fig. 4). These 
data suggest that adenosine and inosine exert their cytoprotec-
tive effects by receptor-independent pathways.
The adenosine deaminase inhibitor EHNA (10 µM) almost 
fully reversed the protective effect of 300-1,000 µM adenosine 
during COGD and following a 4 h-long re-oxygenation period 
(Fig. 5). On the other hand, EHNA did not influence the cyto-
protective effect of inosine in same assay conditions (Fig. 5). 
The adenosine kinase inhibitor ABT 702 (30 µM) signifi-
cantly reversed the protective effect of 300 and 1,000 µM 
adenosine and inosine during COGD and following a 4 h-long 
re-oxygenation period. We also tested both enzyme inhibitors 
in combined administration (Fig. 7). Notably, ABT 702, on its 
own, appeared to have a mild cytoprotective effect in our assay 
(Figs. 6 and 7).
Discussion
The present study utilizes a cell-based model of liver isch-
emia-reperfusion injury in cultured HepG2 cells subjected to 
combined oxygen-glucose deprivation followed by re-oxygen-
ation. Experimental conditions similar to the current ones have 
previously been used in multiple studies in cultured hepatocytes 
and Kupffer cells to mimic conditions of ischemia, in order to 
Figure 3. Dose-response effects of (A and B) adenosine and (C and D) inosine on percent viability values by MTT assay and LDH activities in mOD/min 
in HepG2 cultures exposed to a 14 h-long combined oxygen-glucose deprivation (COGD) and a subsequent 4 h-long re-oxygenation. Each group, except the 
control (CTL) group, was incubated in glucose-free medium under anaerobic conditions for a 14 h-long period and following a 4 h-long re-oxygenation phase 
by normalized glucose and oxygen levels in the cell culture medium and atmosphere. Data are shown as the means ± SEM. White bar is control (CTL, n=16) 
group in the control conditions of the assay, black bar is COGD group (n=32) during COGD without any pharmacological pretreatment, dotted bar shows the 
adenosine pretreatment group at 1, 3, 10, 30, 100, 300, 1,000 and 3,000 µM (ADE) and ruled bar represents the inosine pretreatment group at 1, 3, 10, 30, 100, 
300, 1,000 and 3,000 µM (INO). ADE and INO groups (n=3) were also under COGD conditions. #P<0.05 compared to the CTL group and *P<0.05 compared 
to the COGD group.
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study pathways of cell death, signal transduction, free radical 
and oxidant production and inflammatory responses (28-33). 
Our results demonstrate that both adenosine and inosine exert 
cytoprotective effects in the current model, in a concentra-
tion-dependent manner (when assessed by measurement of 
LDH release and mitochondrial activity by the MTT assay). 
Although in several experimental models the cytoprotective 
effects of adenosine and inosine are known to be dependent 
Figure 4. Effect of adenosine receptor antagonists on the cytoprotective effects of inosine. Confluent HepG2 cultures were subjected to combined oxygen-glucose 
deprivation (COGD, n=32) for 14 h followed by a 4-h-long re-oxygenation period. (A and B) The A1 adenosine receptor antagonist, CDPX, (C and D) the A2A 
adenosine receptor antagonist, CSC, (E and F) the A2B adenosine receptor antagonist, alloxazine, and the A3 adenosine receptor antagonist, (G and H) MRS 1523 
were applied in the indicated concentrations (n=3) 30 min prior to the inosine or adenosine pretreatment (INO or ADE, n=12) and were present throughout the 
COGD period. Viability was measured by the MTT assay (A, C, E and G) and LDH activities (B, D, F and H) were measured from the cell culture supernatant. 
Controls (CTL, n=16) were exposed to hypoxia in complete culture medium. Data are shown as the means ± SEM. #P<0.05 compared to CTL and *P<0.05 
compared to COGD. None of the adenosine receptor antagonists affected the cytoprotective effects of adenosine (data not shown) and inosine during COGD.
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Figure 5. Effect of adenosine deaminase inhibitor (EHNA) on the cytoprotective action of 300-1,000 µM adenosine (ADE) and inosine (INO) in HepG2 
cultures exposed to a 14 h-long hypoxia period and a subsequent 4 h re-oxygenation. Data are shown as the means ± SEM. (A and C) Percent viability values 
by MTT assay and (B and D) LDH activities in mOD/min are shown. Seven groups were studied both of the adenosine and inosine. The COGD group during 
COGD (black bar, n=16), a COGD group plus 10 µM EHNA during COGD (black bar, n=16), groups pre-treated with 300 or 1,000 µM adenosine (ADE) and 
inosine (INO) during COGD (ADE, dotted bar; INO, ruled bar, n=3) and finally groups pre-treated with 300 or 1,000 µM adenosine and inosine plus 10 µM 
EHNA during COGD (ADE 300-1,000 µM + EHNA and INO 300-1,000 µM + EHNA are grey bar, n=3). The white bar is the control (CTL, n=16) group and 
represents the negative control of the assay. #P<0.05 compared to CTL; *P<0.05 compared to the COGD group; and δP<0.05 compared to the 300-1,000 µM 
ADE groups.
Figure 6. Effect of adenosine kinase inhibitor (ABT 702) on the cytoprotective action of 300-1,000 µM adenosine (ADE) and inosine (INO) in HepG2 cultures 
exposed to a 14 h-long hypoxia period and a subsequent 4 h re-oxygenation. Data are shown as the means ± SEM. (A and C) Percent viability values by MTT 
assay and (B and D) LDH activities in mOD/min are shown. Seven groups were studied both of the adenosine and inosine. The COGD group during COGD 
(black bar, n=16), a COGD group plus 30 µM ABT 702 during COGD (black bar, n=16), groups pre-treated with 300 or 1,000 µM adenosine (ADE) and 
inosine (INO) during COGD (ADE, dotted bar; INO, ruled bar, n=3) and finally groups pre-treated with 300 or 1,000 µM adenosine and inosine plus 30 µM 
ABT 702 during COGD (ADE 300-1,000 µM + ABT and INO 300-1,000 µM + ABT are grey bars, n=3). The white bar is the control (CTL, n=16) group and 
represents the negative control of the assay. #P<0.05 compared to CTL; *P<0.05 compared to the COGD group; and δP<0.05 compared to the 300-1,000 µM 
ADE and INO groups.
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on activation of adenosine A2A receptors (11,12,34), the results 
of the current study demonstrate that the protective effect of 
adenosine and inosine in the current experimental conditions 
were not mediated by adenosine receptor-dependent pathways, 
as evidenced by the failure of specific adenosine receptor 
blockers to prevent the protective effects. Although several 
reports suggest a role for cell surface adenosine receptors 
in the reduction of liver reperfusion injury in vivo (35-39), it 
is likely that the location of these receptors is primarily on 
mononuclear cells involved in pro-inflammatory/immune 
responses (as opposed to hepatocytes).
While adenosine receptors failed to play a role in the 
cytoprotective effects of adenosine and inosine described in 
the present study, the data suggest the involvement of receptor-
independent intracellular actions that are related to a direct 
regulation of cellular bioenergetics. We utilized the pharma-
cological inhibitor EHNA to inhibit adenosine deaminase, 
the enzyme that is responsible for the intracellular conversion 
of adenosine to inosine. EHNA significantly decreased the 
viability of the adenosine-treated cells subjected to COGD 
and also significantly increased the LDH release from the 
cells (Fig. 5). On the other hand, EHNA did not reduce the 
protective effect of inosine. These data are consistent with the 
hypothesis that, ultimately, an intracellular action, mediated 
by inosine, is responsible for the protective effect of adenosine. 
Our interpretation of the experimental findings is that, similar 
to astrocytes and kidney epithelial cells subjected to hypoxia 
and re-oxygenation (13,14,23), the conversion of adenosine to 
inosine and its subsequent metabolism to ribose-phosphate, 
followed by ATP generation via the pentose phosphate pathway 
are responsible for the observed cytoprotective effects.
Haun et al (23), Jurkowitz et al (40) and Litsky et al (41) 
demonstrated that the ribose moiety of the adenosine and 
inosine can be used as a precursor for phosphorylated 
Figure 7. Collective effect of adenosine deaminase inhibitor (EHNA) and adenosine kinase inhibitor (ABT 702) on the cytoprotective actions of 300-1,000 µM 
adenosine (ADE) and inosine (INO) in HepG2 cultures exposed to a 14 h-long hypoxia period and a subsequent 4 h re-oxygenation. Data are shown as the 
means ± SEM. (A and C) Percent viability values by MTT assay and (B and D) LDH activities in mOD/min are shown. Seven groups were studied both of the 
adenosine and inosine. The COGD group during COGD (black bar, n=32), a COGD group plus 30 µM ABT 702 during COGD (black bar, n=3), a COGD group 
plus 10 µM EHNA during COGD (black bar, n=3), a COGD group plus 30 µM ABT 702 and 10 µM EHNA in combination during COGD (black bar, n=3), groups 
pre-treated with 300-1,000 µM adenosine (ADE) and inosine (INO) during COGD (ADE, dotted bar; INO, ruled bar, n=3) and finally groups pre-treated with 
300 or 1,000 µM adenosine and inosine plus 30 µM ABT 702 or 10 µM EHNA during COGD (ADE/INO 300/1,000 µM + ABT 702/EHNA or in combination 
are grey bars, n=3). The white bar is the control (CTL, n=16) group and represents the negative control of the assay, subjected to hypoxia in complete culture 
medium. #P<0.05 compared to CTL; *P<0.05 compared to the COGD group; and δP<0.05 compared to the 300-1,000 µM ADE and INO groups.
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glycolytic intermediates in reactions catalyzed by enzymes 
of the pentose phosphate pathway. The first reaction in this 
pathway is the phosphorolysis of inosine and the formation 
of ribose 1-phosphate or hypoxanthine, which is catalyzed by 
purine nucleoside phosphorylase. Three ribose 1-phosphates 
are isomerized to three D-ribose 5-phosphates, which then 
convert to two fructose 6-phosphates and one glyceraldehyde 
3-phosphate, via transaldolases and transketolases of the 
pentose phosphate pathway. These phosphorylated intermedi-
ates enter the glycolytic pathway yielding a net production of 
8 moles ATP and 5 moles NADH + H+ from three molecules of 
ribose 1-phosphate (Fig. 8). All produced NADH + H+ convert 
to NAD+ by lactate dehydrogenase (LDH) in anaerobic condi-
tions. However, after a while, lactate accumulates resulting in 
cellular acidosis. For abolishing the acidosis lactate degrada-
tion to pyruvate and its further decomposition in the Krebs 
cycle at the presence of oxygen is indispensable.
From the same molar amount (3 moles) of extracellular 
(or exogenous) glucose: 6 moles of ATP and 6 moles of 
NADH + H+ are produced during the glycolysis (Fig. 8). From 
the breakdown of glycogen, 3 moles of intracellular glucose-1 
phosphate can produce a maximum of 9 moles of net ATP and 
6 moles of NADH + H+. On the other hand, from 3 moles of 
adenosine or inosine, the cell can produce net 8 moles of ATP 
and 5 moles of NADH + H+. Thus, the cells tend to elevate the 
intracellular NAD+/NADH + H+ ratio, thereby regenerating as 
many NADH + H+ molecules as possible within a short time. 
On the other hand, NAD+ molecules are required to 
continue the glycolysis and lactate intermediates inhibit the 
further regeneration if the NADH + H+ molecules thereby 
impairing glycolysis. During excessive hypoxia, the accumu-
lation of NADH + H+ occurs and, subsequently, inhibition of 
several enzymes (citrate synthase, isocitrate-dehydrogenase, 
α-ketoglutarate dehydrogenase) occurs, thereby interfering 
with the Krebs cycle, which is controlled by the ratio of 
the NADH/NAD+ and the ATP/ADP. Furthermore, during 
massive anaerobic conditions, NADH + H+ accumulation 
also leads to an inhibition of glycolysis. In summary, during 
COGD, adenosine and inosine may delay the accumulation 
of NADH + H+ and they can serve as a source of energy to 
maintain basal cellular function. In prolonged hypoxia, the 
accumulation of NADH + H+ is inevitable and the glycolysis 
and the Krebs cycle are both inhibited. Thus, long-term absence 
of the terminal oxidation and the regeneration of NADH + H+ 
to NAD+ result in severe cellular energy imbalance.
The results of the present study also demonstrated that 
the administration of the adenosine kinase inhibitor ABT 702 
reversed all of the protective effects of adenosine and inosine. 
These findings are consistent with the hypothesis that adenosine 
kinase is responsible for producing AMP, ADP, and, eventu-
ally, ATP from adenosine. When sufficient ADP molecules 
are present in the cells, ATP can be created from ADP both 
via the adenosine kinase-mediated route and via the pentose 
phosphate pathway. The inhibition of the adenosine kinase 
pathway by ABT 702 results in less ADP production in the 
adenosine kinase-mediated pathway, which induces less ATP 
generation in the pentose phosphate shunt as well. This mecha-
nism explains that, i) ATP production of the pentose phosphate 
pathway depends on the amount of ADP molecules derived 
from the adenosine kinase mediated route, and ii) provides 
evidence that administration of adenosine kinase inhibitor 
ABT 702 reversed all of the protective effects of adenosine and 
inosine. Furthermore, adenosine kinase inhibitor (ABT 702) 
administration without exogenous adenosine or inosine affords 
a mild cytoprotective effect, but prevents the cytoprotection 
provided by exogenous adenosine or inosine (Figs. 6 and 7).
Figure 8. Scheme representing some of the proposed metabolic pathways for the conversion of adenosine and inosine into different substrates for the glycolytic 
pathway. The diagram also shows an alternative way to produce energy in the absence of glucose during hypoxic injury.
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Our data and the above considerations, taken together, 
indicate that adenosine and inosine may exert some of their 
cytoprotective effects under our current experimental condi-
tions by stepping in as an emergency energy source, when 
glucose is insufficient to support cellular functions. This 
hypothesis is supported both by several reports in the litera-
ture where cellular ATP levels were elevated in ischemic or 
hypoxic cells treated with adenosine or inosine (23,40,42-44) 
as well as by our measurements (13,14). Although we have 
not directly measured the transport of adenosine or inosine 
into the cells, previous studies have demonstrated that these 
purines can readily enter the cells (23,40). We propose that 
the two processes, i) degradation of adenosine and inosine via 
the pentose-phosphate pathway, and ii) the phosphorylation of 
adenosine to AMP, are required in a well-balanced parallel 
fashion. Our hypothesis is that both pathways are necessary at 
the same time to support the generation of ATP under hypoxic 
conditions. The first process provides the energy, while the 
second one supplies the substrate (e.g. adenosine, AMP, ADP) 
to convert it into a high energy intermediate that conserves it 
in a ready-to-use form. Markedly, the combined blockage of 
adenosine deaminase (by EHNA) and adenosine kinase (by 
ABT 702) resulted in no further reduction in cell viability after 
COGD (as compared to either inhibitor), which supports that 
these enzymes take part in the same cytoprotective mecha-
nism (Fig. 7). 
In conclusion, it is likely that the cytoprotective effects of 
adenosine and inosine involve multiple, parallel and interre-
lated mechanisms under the current experimental conditions. 
During ischemia and inflammation, the concentration of 
purine metabolites increases dramatically in the extracellular 
space. ATP degrades into AMP and subsequently to adenosine, 
which may be released from the cells and appears in the extra-
cellular space. Inosine can be formed from adenosine with an 
adenosine deaminase enzyme, which occurs both intra- and 
extracellularly. Consistent with these notions, there are several 
reports that demonstrate the cytoprotective effect of endog-
enously formed adenosine in the context of acute ischemic 
injury of the liver (45,46). 
The current study shows that adenosine and inosine are 
cytoprotective on HepG2 cultures exposed to combined 
oxygen-glucose deprivation. This protective effect is not medi-
ated by a receptor-dependent pathway, but it is likely mediated 
by maintenance of cellular bioenergetics due to the utilization 
of adenosine and inosine as alternative substrates for ATP 
generation.
While the therapeutic utilization of adenosine as a hepato-
protective agent in vivo is difficult due to its short half-life and 
adverse cardiovascular side-effect profile, inosine may emerge 
as a potential candidate. Indeed, several recent studies have 
demonstrated that administration of inosine can be protective 
against various forms of ischemic conditions (7-10). The current 
results may provide a mechanistic explanation to the previously 
reported protective effect of inosine in vitro as an adjuvant to 
organ storage solutions (47) or in vivo as a protective agent in a 
rat model of hepatic reperfusion injury (48) and can stimulate 
further studies to explore whether inosine has the potential to 
improve cellular bioenergetics and to protect hepatocytes in 
various forms of liver injury, including various forms of warm 
ischemia or cold ischemia associated with liver transplantation.
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